NCT00135187View on ClinicalTrials.gov

Study of Combination Therapy With VELCADE, Doxil, and Dexamethasone (VDd) in Multiple Myeloma

NACompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

July 31, 2004

Primary Completion Date

August 31, 2006

Study Completion Date

December 31, 2007

Conditions
Multiple Myeloma
Interventions
DRUG

VELCADE

"VELCADE will be used biweekly at 1.3 mg/m2 during week 1 and 2 on (days~1, 4, 8, and 11) followed by a 1-week break."

DRUG

Doxil

Doxil will be administered at 30 mg/m2 IV on day 4

DRUG

Dexamethasone

Dexamethasone at 40 mg during the first cycle and 20 mg during cycles 2-6 po or IV daily on days of VELCADE and day after VELCADE (i.e. days 1, 2, 4, 5, 8, 9, 11, 12). The patient will be treated for six 3-week cycles followed by three 5-week maintenance cycles.

Trial Locations (1)

48109

University of Michigan Cancer Center, Ann Arbor

All Listed Sponsors
lead

University of Michigan Rogel Cancer Center

OTHER

NCT00135187 - Study of Combination Therapy With VELCADE, Doxil, and Dexamethasone (VDd) in Multiple Myeloma | Biotech Hunter | Biotech Hunter